Navigation Links
BT Pushes for R&D Innovation at Bio-IT World Conference
Date:4/14/2011

BOSTON, April 14, 2011 /PRNewswire/ -- BT (NYSE: BT) shared its vision of the future of pharma R&D and the application of cloud computing strategies to pharma research at the Bio-IT World Conference & Expo held this week in Boston. This vision reflects BT's strong capabilities and increasing specialization around a number of industry sectors. Many of the world's leading pharmaceutical companies rely on BT to support their strategy in terms of globalization, operational effectiveness and innovation cycles.

In a keynote panel session, Yury Rozenman, Global Head of Marketing, Pharmaceutical and Life Sciences Sector, BT Global Services, described the pressures currently facing pharma R&D, as well as the opportunities to improve the R&D and innovation process by seamlessly connecting partners, suppliers, biotechs, devices and diagnostic, regulatory agencies and clinical research organizations in an R&D ecosystem.

Rozenman said: "An R&D innovation ecosystem is essentially a networked cooperative: the more participants, the greater value; the more contribution by individual participants, the less expense to use the ecosystem."

Rozenman noted that the benefits of embracing the R&D innovation ecosystem model include increased speed to trial, leading to savings of millions of dollars per drug, reduced costs via out-tasking, and more effective collaboration between industry players and partners, leading to improved research productivity. The differentiator is the ability to integrate not just data and applications but the human resources of the global R&D pharma community.

Leading a session on cloud computing at the same event, Neil Lock, IT Services Program Director, BT Global Services, examined the practical aspects of cloud computing as it relates to pharma R&D.

Lock said: "Much of the debate, hype and headlines about cloud computing focuses on technology rather than benefits.  And frankly, many are suffering from cloud fatigue.  Pharma organizations want to realize the benefits of cloud computing, but they first need to get beyond the fog of confusion surrounding cloud terminology, focus on deliverable business results and look at what they really have to do to make cloud solutions work for them."

Lock offered real-world examples of how migrating to cloud applications has led to greater flexibility, more reliable services, reduced financial risk, and lower costs.  Lock also discussed the evolution to "smart communities," which describes the way in which customers, software vendors and service providers need to work together and collaborate to deliver real value from IT Investments made.

Bas Burger, President, Global Commerce, BT Global Services said: "The vision we shared this week in Boston demonstrates how the R&D efforts of pharmaceutical companies can benefit from BT's industry focused assets in product portfolio, solution designs and infrastructure as well as from our sector-specific customer management and service teams. By focusing on the pharmaceutical sector's unique needs, and offering customers access to teams with decades of experience solving problems in their sector, BT is seen as a reliable partner. This is about specialist people, portfolio and intellectual property, embedded throughout our business. Our customers can leverage many of our market leading assets. We have been serving some of the world's biggest brands in this industry for many years, and have a track record of helping them thrive."

About BT

BT is one of the world's leading providers of communications solutions and services operating in more than 170 countries.  Its principal activities include the provision of networked IT services globally; local, national and international telecommunications services to our customers for use at home, at work and on the move; broadband and internet products and services and converged fixed/mobile products and services.  BT consists principally of four lines of business: BT Global Services, Openreach, BT Retail and BT Wholesale.

In the year ended 31 March 2010, BT Group's revenue was 20,911 million pounds.

British Telecommunications plc (BT) is a wholly-owned subsidiary of BT Group plc and encompasses virtually all businesses and assets of the BT Group.  BT Group plc is listed on stock exchanges in London and New York.

For more information, visit www.bt.com/aboutbt


'/>"/>
SOURCE BT
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Chasing Zero Summit Pushes for Zero Tolerance Approach to Hospital-Acquired Infections
2. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
3. LOREAL and Hurel Corporation Announce R&D Collaboration to Develop a Non-Animal Alternative, Microfluidic Biochip
4. Micromet Highlights Clinical Plans and Regulatory Strategy for Lead Product Candidate Blinatumomab at its Annual R&D Day
5. R&D Investment by U.S. Biopharmaceutical Companies Remains Strong Despite Ongoing Economic Challenges
6. R&D Investment by U.S. Biopharmaceutical Companies Increases to Record $65.3 Billion, Study Finds
7. Kendle Director of Global Safety and Pharmacovigilance, Drew Kilpatrick, PhD, Named One of Ten Notable People in R&D
8. Gelesis Unveils Novel Non-Invasive Capsulated Device for Obesity and Presents Clinical Data; Appoints Former Pfizer R&D President to Board
9. NeoStem, Inc. Officially Launches Adult Stem Cell Collection Center and R&D Laboratory in Cambridge, Massachusetts
10. Global Pharmaceutical R&D Productivity Declining According to Thomson Reuters, CMR International
11. Pfizer Inc and GoIndustry DoveBid Partner to Auction Surplus Equipment from R&D Facilities Across the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... Mich. , Aug. 7, 2017 Diplomat Pharmacy, ... of Joel Saban as president, effective Aug. 7, ... Urick has decided to pursue other interests and will ... "During his tenure, Paul has served us in multiple leadership ... Specialty Pharmacy in Jun. 2015 and has provided decisive, strategic ...
(Date:8/7/2017)... , Aug. 7, 2017  Endo International plc ... reached agreements to resolve virtually all known U.S. mesh ... discussions to resolve the known remaining U.S. claims at ... payments beginning in the fourth quarter of 2017 and ... of its second quarter 2017 results, the Company intends ...
(Date:8/4/2017)... CINCINNATI , Aug. 3, 2017  Agragen, ... science company active in the biopharmaceutical, nutraceutical, and ... its development of its lead drug candidates, AGR131.  ... a proinflammatory cytokine from the blood of patients ... psoriasis, and inflammatory bowel disease. ...
Breaking Medicine Technology:
(Date:8/22/2017)... ... August 22, 2017 , ... John Stewart joins Privis ... Member for t4 Leadership Development & Consulting. He has spent his career focusing ... physician leadership development, servant leadership, data driven process improvement, and supportive technology. These ...
(Date:8/21/2017)... (PRWEB) , ... August 22, 2017 , ... ... but not without risk to health and safety. By learning and implementing best ... eliminated. , In this webinar, attendees will gain a better understanding of ...
(Date:8/21/2017)... ... ... Five chefs from local senior assisted living homes will serve Mediterranean-inspired gourmet ... be able to vote for their favorite Chef among the following: , GREECE, Chef ... Cheese Sauce & Garlic Pita Crisp, Greek Mountain Ice Tea , ITALY, Chef Gabriel ...
(Date:8/21/2017)... ... , ... The American Hospital Association (AHA) has elected Claire Zangerle, Chief Nurse ... Board of Trustees for a three-year term beginning January 1, 2018. , The ... that are committed to the improvement of health in their communities. Founded in 1898, ...
(Date:8/20/2017)... ... August 20, 2017 , ... HIPAA Solutions, LC ... has assisted multiple clients in successfully passing audits such as Office of Civil ... (AICPA SOC Level 2), and State Data Use Agreement Audits. , HIPAA ...
Breaking Medicine News(10 mins):